Plasmapheresis during cardiopulmonary bypass: A proposed treatment for presensitized cardiac transplantation patients

Douglas F Larson, D. K. Elkund, F. Arabia, J. G. Copeland

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Potential thoracic organ transplantation recipients who have positive cytotoxic antibody screens as quantified panel reactive antibodies (PRA) are at risk for immediate or long-term immunologic events that may affect the donor organ. The patient population at risk includes those who are supported with cardiac assist devices, multiparous women, and individuals receiving numerous homologous blood products. We treated three highly positive PRA patients with intraoperative plasmapheresis coupled to the cardiopulmonary bypass system to remove sufficient cytotoxic antibody. Upon the availability of donor hearts of an unknown HLA type, intraoperative plasmapheresis was performed using a Cobe Spectra Plasmapheresis system coupled to a Terumo CXSX 18 oxygenator system. Three plasma volume exchanges of fresh frozen plasma (FFP) were performed while the patients were on cardiopulmonary bypass. One to one and one-half plasma volume exchange plasmaphereses were performed with a declining schedule for the next 30 days post-transplantation in combination with aggressive B-cell specific immunosuppressive therapy. The three patients are NYHA functional class I and free of rejection at 6 months post- transplantation. In conclusion, intraoperative plasmapheresis is effective and safe for the patient who would not be otherwise transplanted because of markedly elevated PRAs.

Original languageEnglish (US)
Pages (from-to)177-183
Number of pages7
JournalJournal of Extra-Corporeal Technology
Volume31
Issue number4
StatePublished - 1999

Fingerprint

Plasmapheresis
Heart Transplantation
Cardiopulmonary Bypass
Plasma Exchange
Antibodies
Plasma Volume
Transplantation
Tissue Donors
Oxygenators
Therapeutics
Organ Transplantation
Immunosuppressive Agents
Appointments and Schedules
B-Lymphocytes
Thorax
Equipment and Supplies

Keywords

  • Cardiac transplantation
  • Cardiopulmonary bypass
  • Panel reactive antibody
  • Plasmapheresis

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Plasmapheresis during cardiopulmonary bypass : A proposed treatment for presensitized cardiac transplantation patients. / Larson, Douglas F; Elkund, D. K.; Arabia, F.; Copeland, J. G.

In: Journal of Extra-Corporeal Technology, Vol. 31, No. 4, 1999, p. 177-183.

Research output: Contribution to journalArticle

@article{a8eaeebaf3b14d31a29295b83d9d6b32,
title = "Plasmapheresis during cardiopulmonary bypass: A proposed treatment for presensitized cardiac transplantation patients",
abstract = "Potential thoracic organ transplantation recipients who have positive cytotoxic antibody screens as quantified panel reactive antibodies (PRA) are at risk for immediate or long-term immunologic events that may affect the donor organ. The patient population at risk includes those who are supported with cardiac assist devices, multiparous women, and individuals receiving numerous homologous blood products. We treated three highly positive PRA patients with intraoperative plasmapheresis coupled to the cardiopulmonary bypass system to remove sufficient cytotoxic antibody. Upon the availability of donor hearts of an unknown HLA type, intraoperative plasmapheresis was performed using a Cobe Spectra Plasmapheresis system coupled to a Terumo CXSX 18 oxygenator system. Three plasma volume exchanges of fresh frozen plasma (FFP) were performed while the patients were on cardiopulmonary bypass. One to one and one-half plasma volume exchange plasmaphereses were performed with a declining schedule for the next 30 days post-transplantation in combination with aggressive B-cell specific immunosuppressive therapy. The three patients are NYHA functional class I and free of rejection at 6 months post- transplantation. In conclusion, intraoperative plasmapheresis is effective and safe for the patient who would not be otherwise transplanted because of markedly elevated PRAs.",
keywords = "Cardiac transplantation, Cardiopulmonary bypass, Panel reactive antibody, Plasmapheresis",
author = "Larson, {Douglas F} and Elkund, {D. K.} and F. Arabia and Copeland, {J. G.}",
year = "1999",
language = "English (US)",
volume = "31",
pages = "177--183",
journal = "Journal of Extra-Corporeal Technology",
issn = "0022-1058",
publisher = "American Society of Extra-Corporeal Technology",
number = "4",

}

TY - JOUR

T1 - Plasmapheresis during cardiopulmonary bypass

T2 - A proposed treatment for presensitized cardiac transplantation patients

AU - Larson, Douglas F

AU - Elkund, D. K.

AU - Arabia, F.

AU - Copeland, J. G.

PY - 1999

Y1 - 1999

N2 - Potential thoracic organ transplantation recipients who have positive cytotoxic antibody screens as quantified panel reactive antibodies (PRA) are at risk for immediate or long-term immunologic events that may affect the donor organ. The patient population at risk includes those who are supported with cardiac assist devices, multiparous women, and individuals receiving numerous homologous blood products. We treated three highly positive PRA patients with intraoperative plasmapheresis coupled to the cardiopulmonary bypass system to remove sufficient cytotoxic antibody. Upon the availability of donor hearts of an unknown HLA type, intraoperative plasmapheresis was performed using a Cobe Spectra Plasmapheresis system coupled to a Terumo CXSX 18 oxygenator system. Three plasma volume exchanges of fresh frozen plasma (FFP) were performed while the patients were on cardiopulmonary bypass. One to one and one-half plasma volume exchange plasmaphereses were performed with a declining schedule for the next 30 days post-transplantation in combination with aggressive B-cell specific immunosuppressive therapy. The three patients are NYHA functional class I and free of rejection at 6 months post- transplantation. In conclusion, intraoperative plasmapheresis is effective and safe for the patient who would not be otherwise transplanted because of markedly elevated PRAs.

AB - Potential thoracic organ transplantation recipients who have positive cytotoxic antibody screens as quantified panel reactive antibodies (PRA) are at risk for immediate or long-term immunologic events that may affect the donor organ. The patient population at risk includes those who are supported with cardiac assist devices, multiparous women, and individuals receiving numerous homologous blood products. We treated three highly positive PRA patients with intraoperative plasmapheresis coupled to the cardiopulmonary bypass system to remove sufficient cytotoxic antibody. Upon the availability of donor hearts of an unknown HLA type, intraoperative plasmapheresis was performed using a Cobe Spectra Plasmapheresis system coupled to a Terumo CXSX 18 oxygenator system. Three plasma volume exchanges of fresh frozen plasma (FFP) were performed while the patients were on cardiopulmonary bypass. One to one and one-half plasma volume exchange plasmaphereses were performed with a declining schedule for the next 30 days post-transplantation in combination with aggressive B-cell specific immunosuppressive therapy. The three patients are NYHA functional class I and free of rejection at 6 months post- transplantation. In conclusion, intraoperative plasmapheresis is effective and safe for the patient who would not be otherwise transplanted because of markedly elevated PRAs.

KW - Cardiac transplantation

KW - Cardiopulmonary bypass

KW - Panel reactive antibody

KW - Plasmapheresis

UR - http://www.scopus.com/inward/record.url?scp=0033504396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033504396&partnerID=8YFLogxK

M3 - Article

C2 - 10915474

AN - SCOPUS:0033504396

VL - 31

SP - 177

EP - 183

JO - Journal of Extra-Corporeal Technology

JF - Journal of Extra-Corporeal Technology

SN - 0022-1058

IS - 4

ER -